A pivotal US panel is set to vote on a potential shift in the infant hepatitis B vaccine recommendation, sparking debate and concern. After a heated discussion and a delay, the federal vaccine advisory committee, ACIP, will decide whether to change the long-standing advice to immunize all newborns against hepatitis B. This decision carries significant implications for childhood health in the US, as the vaccine has been administered to over 1.4 billion people over three decades. The meeting in Atlanta, attended by a panel hand-picked by Robert F. Kennedy Jr., an anti-vaccine advocate, has raised eyebrows. The panel's composition includes individuals with a history of opposing vaccines, adding a layer of controversy to the debate. The discussion centered on the timing of the vaccine, with questions raised about the evidence supporting its administration before 30 days. Experts highlight the limited data on long-term risks, leading to a speculative atmosphere. The panel's recommendations carry weight, as they advise the CDC, and any changes could have far-reaching consequences. The panel's membership has also undergone recent changes, with the departure of Dr. Martin Kulldorff and the appointment of Dr. Kirk Milhoan, a critic of the COVID vaccine. The panel's decisions and the influence of its members, some with anti-vaccine leanings, have sparked concern and raised questions about the potential impact on public health policies.
